Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE)

Active, not recruiting

Conditions: Hereditary Angioedema (HAE)

Interventions: Other: No Intervention

First Posted Date: 2022-07-22

Last Posted Date: 2024-12-24

Lead Sponsor: Takeda

Target Recruit Count: 50

Registration Number: NCT05469789

Locations: 🇬🇧
Barts Health NHS Trust, London, England, United Kingdom

A Study of RYMPHYSIA for Alpha1-Proteinase Inhibitor (A1PI) Therapy in Adults With A1PI Deficiency and Chronic Obstructive Pulmonary Disease (COPD)-Emphysema

Phase 4

Withdrawn

Conditions: Alpha1-Antitrypsin Deficiency
Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Biological: RYMPHYSIA
Biological: Another Available A1PI

First Posted Date: 2022-07-20

Last Posted Date: 2023-05-06

Lead Sponsor: Takeda

Registration Number: NCT05466747

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Phase 3

Completed

Conditions: Hereditary Angioedema (HAE)

Interventions: Drug: Lanadelumab

First Posted Date: 2022-07-15

Last Posted Date: 2024-12-13

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT05460325

Locations: 🇨🇳
Yantai Yuhuangding Hospital, Yantai, Shandong, China
🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan, Hubei, China
🇨🇳
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 1 locations

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

Phase 3

Recruiting

Conditions: Crohn's Disease
Ulcerative Colitis

Interventions: Drug: Vedolizumab IV
Other: No Intervention

First Posted Date: 2022-07-05

Last Posted Date: 2024-03-06

Lead Sponsor: Takeda

Target Recruit Count: 240

Registration Number: NCT05442567

Locations: 🇦🇺
Children's Hospital at Westmead, Westmead, New South Wales, Australia
🇺🇸
Goryeb Children's Hospital, Morristown, New Jersey, United States
🇺🇸
Texas Children's Hospital, Houston, Texas, United States

and more 65 locations

A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma

Phase 4

Active, not recruiting

Conditions: T-Cell Lymphoma

Interventions: Drug: Brentuximab vedotin

First Posted Date: 2022-07-05

Last Posted Date: 2023-09-18

Lead Sponsor: Takeda

Target Recruit Count: 10

Registration Number: NCT05442554

Locations: 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

and more 1 locations

A Proof-of-concept Study to Reduce Treatment Burden in Haemophilia Participants Receiving Factor VIII and Factor IX Infusions

Not Applicable

Completed

Conditions: Hemophilia

Interventions: Device: Virtual-reality (VR) Based Solution

First Posted Date: 2022-06-29

Last Posted Date: 2024-05-06

Lead Sponsor: Takeda

Target Recruit Count: 24

Registration Number: NCT05437211

Locations: 🇫🇷
Hôpital de Hautepierre - Pôle MIRMED, Strasbourg, Alsace-Champagne-Ardenne-Lorraine, France
🇫🇷
Hôpital Hôtel-Dieu, Nantes, Pays De La Loire, France
🇫🇷
CHU Pellegrin, Bordeaux, Nouvelle-Aquitaine, France

and more 3 locations

A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea

Recruiting

Conditions: Inflammatory Bowel Disease (IBD)
Crohn's Disease
Ulcerative Colitis

First Posted Date: 2022-06-23

Last Posted Date: 2024-10-07

Lead Sponsor: Takeda

Target Recruit Count: 600

Registration Number: NCT05428345

Locations: 🇰🇷
Donggguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

A Spanish Medical Record Review of Clinical Characteristics and Outcomes in Non-small Cell Lung Cancer Participants With EGFR Exon 20 Insertion

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)

First Posted Date: 2022-06-15

Last Posted Date: 2023-09-06

Lead Sponsor: Takeda

Target Recruit Count: 76

Registration Number: NCT05419700

Locations: 🇪🇸
Hospital Universitario de Navarra (HUN), Pamplona, Navarra, Spain
🇪🇸
Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain
🇪🇸
Hospital Universitario Virgen de la Victoria, Malaga, Andalucia, Spain

and more 12 locations

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Recruiting

Conditions: Hereditary Angioedema (HAE)

Interventions: Drug: Lanadelumab

First Posted Date: 2022-05-31

Last Posted Date: 2024-07-25

Lead Sponsor: Takeda

Target Recruit Count: 100

Registration Number: NCT05397431

Locations: 🇯🇵
Takeda selected site, Tokyo, T, Japan

A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Practice in Poland

Active, not recruiting

Conditions: Inflammatory Bowel Disease (IBD)
Crohn's Disease
Ulcerative Colitis

First Posted Date: 2022-05-20

Last Posted Date: 2024-10-09

Lead Sponsor: Takeda

Target Recruit Count: 165

Registration Number: NCT05384080

Locations: 🇵🇱
Uniwersytecki Szpital Kliniczny, Wroclaw, Dolnoslskie, Poland
🇵🇱
Szpital Uniwersytecki w Krakowie, Krakow, Malopolskie, Poland
🇵🇱
Samodzielny Publiczny Szpital Kliniczny Nr 4 W Lublinie, Lublin, Lubelskie, Poland

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy